Wire · opportunities
HLB wins FDA nod for FGFR2 bile duct cancer drug, tests Korea investor mood
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 28 September 2026 · Fusion42 review
HLB received FDA approval for the bile duct cancer drug Rifiktu (lirafugratinib), marking its first US market entry via an externally licensed drug rather than its long-pursued internal liver cancer treatments. The approval offers full marketing rights and 14 years of patent protection, with ongoing efforts to expand indications and obtain EMA approval.
This Wire brief sits within Fusion42's coverage of Biotech, and 6 sources have reported it between 21 Sep 2026 and 28 Sep 2026.
◆ ◆ The Wire takeaway
You must reassess your US market entry strategies as external licensing can outpace internal development for approval timelines. This FDA nod opens a direct sales channel without confirmatory trial risks, so prioritise commercial groundwork and patient access plans now.
◆ Coverage
6 sources · first reported 21 Sep 2026 · latest 28 Sep 2026
◆ Related on Wire
◆ Topics